ABTL0812

DRUG5 trials

Sponsors

Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron, Ability Pharmaceuticals S.A., Ability Pharmaceuticals SL

Conditions

CancerMetastatic pancreatic ductal adenocarcinomaPancreatic CancerRelapsed/refractory neuroblastoma and other solid tumours

Phase 1

Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients

CompletedNCT02201823

Ability Pharmaceuticals SLCancer

Start: 2014-02-28End: 2015-04-30Updated: 2015-07-02

A Study of ABTL0812 in Pancreatic Cancer

SuspendedNCT03417921

Ability Pharmaceuticals SLPancreatic Cancer

Start: 2021-04-26End: 2025-12-31Target: 60Updated: 2025-10-01

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

CompletedNCT04431258

Ability Pharmaceuticals SLPancreatic Cancer

Start: 2021-05-06End: 2024-01-10Updated: 2024-03-18

A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Active, not recruitingCTIS2024-515379-36-00

Ability Pharmaceuticals S.A.Metastatic pancreatic ductal adenocarcinoma

Start: 2020-08-04Target: 98Updated: 2025-09-05

A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours

RecruitingCTIS2023-504246-64-02

Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De HebronRelapsed/refractory neuroblastoma and other solid tumours

Start: 2025-06-04Target: 48Updated: 2025-09-05

Related Papers

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

2024-07-224 citations

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.

2021-02-1220 citations

Abstract LB-C18: First-in-Human Clinical Trial of ABTL0812, a Compound that Inhibits PI3K/Akt/mTOR Pathway by Upregulating TRIB3, in Patients with Advanced Solid Tumors

Molecular Cancer Therapeutics2015-12-01

Abstract 672: ABTL0812, a new antitumor drug that inhibits the axis Akt/mTOR through a novel mechanism of action

Cancer Research2015-08-01

Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-203 citations